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Abstract
Microphthalmia-associated transcription factor (MITF) controls melanocyte survival and differentiation
through directly regulating the expression of the tyrosinase (TYR) and tyrosinase-related proteins 1 and 2
(TYRP1 and TYRP2) genes. MITF mutations have been reported to result in an abnormal melanocyte devel-
opment and lead to Waardenburg syndrome type 2 (WS2), characterized by variable degrees of sensorineu-
ral hearing loss and patchy regional distribution of hypopigmentation. Recently, MITF was also indicated as
a causative gene for a more severe syndrome, the Tietz Syndrome (TS), characterized by generalized hy-
popigmentation and complete hearing loss. However, few functional studies have been performed to com-
pare the diseases-causing mutations. Here, we analyzed the in vitro activity of two recent identified WS2-as-
sociated mutation (p.R217I and p.T192fsX18) and one TS-associated mutation p.N210K. The R217I MITF
retained partial activity, normal DNA-binding ability and nuclear distribution, whereas the T192fsX18 MITF
failed to activate TYR promoter due to loss of DNA-binding activity, and aberrant subcellular localization.
The aberrant subcellular localization of T192fsX18 MITF may be caused by deletion of a putative nuclear
localization signal (NLS) at aa 213-218 (ERRRRF). Indeed, MITF with deletion of the NLS fragment failed
to translocate into the nucleus and activated the TYR promoter. Tagging this NLS to GFP promoted the green
fluorescence protein (GFP) translocated into the nucleus. The surprising finding of our study is that a TS-as-
sociated MITF mutation, N210K, showed comparable in vitro activity as WT. Thus, the possible involve-
ment of MITF in TS and its underlying mechanisms still need further investigation.
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Introduction
Microphthalmia-associated transcription factor
(MITF), a basic helix-loop-helix leucine zipper (bHL-
HZip) transcription factor, plays a key role in survival
and differentiation of melanocytes [1-4]. In melanocytes,
MITF regulates the expression of major melanogenic
genes such as tyrosinase (TYR), tyrosinase-related pro-
teins-1 (TYRP1) and tyrosinase-related proteins-2
(TYRP2) [5-7]. MITF directly upregulates the expression
of TYR, TYRP1 and TYRP2 by binding to the E-box
motif (CANNTG) within the promoter [4, 7-10]. The TYR,
TYRP1 and TYRP2 genes encode the three enzymes re-
quired for normal melanin synthesis or melanogenesis in
melanocytes [8, 10-12]. These enzymes, specifically tyrosi-
nase, are key players in the melanocyte differentiation,
as demonstrated by the dramatic consequences of their
mutations on melanin pigment production [13].
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Homozygous Mitf mutant mice can normally survive
but are microphthalmic, deaf, and completely white due
to lacking melanocytes [2，14], whereas heterozygous Mitf
mutant mice show the striking phenotype of belly spot-
ting [15]. In human, MITF mutations are associated with ~
15% of WS2. WS is an autosomal dominantly inherited
disorder of neural crest cells (NCC) characterized by sen-
sorineural deafness and abnormal pigmentation of the
hair, skin and iris [16]. Clinically, WS is divided into four
types (WS1-4) based on the presence or absence of addi-
tional symptoms. Absence of additional features character-
izes WS2. Moreover, mutations in MITF have also been
shown to cause TS (albinism-deafness syndrome) [17-19],
which is inherited in a fully penetrant autosomal domi-
nant fashion, characterized by congenital profound deaf-
ness and a uniform dilution of pigmentation instead of
the patchy depigmentation seen in WS. However, no
functional study has been performed to understand how
different mutations in the MITF gene cause two diseases.
We previously reported two mutations c.650G>T (p.
R217I) and c.575delC (p.T192fsX18) in the MITF gene
in two different families with WS2 [20]. To understand the
functional consequences of the two mutations, we ana-
lyzed the subcellular distribution, expression and in vitro
activities of the two mutations. Furthermore, we also ana-
lyzed the in vitro activities of c.630G>C (p.N210K), a
missense mutation reported in TS patients [17].
Materials and Methods
Reporter and Expression Constructs
The luciferase reporter containing the TYR promoter
(pGL3-Tyr-Luc) and the expression constructs had been
described previously and were kindly provided by J.
Vachtenheim [21]. The pGL3-Tyr-Luc plasmid contained
the promoter region of the human TYR gene (-300 to +
80). To generate MITF tagged with 3×Flag at the N-ter-
minus (Flag-MITF), full length MITF cDNA (GenBank
accession no. NM 000248.2) was amplified from pC-
MV-MITF-HA and subcloned into pCMV-3 × Flag (Sig-
ma, St Louis, WA, USA). QuikChange II Site-Directed
Mutagenesis Kit (GE Healthcare, Chalfont St. Giles,
Buckinghamshire, UK) was used to introduce R217I,
T192fsX18 and N210K mutations into MITF. In addi-
tion, we generated expression plasmid encoding for a
mutant MITF lacking NLS (213ERRRRF218), termed
pCMV-MITF∆NLS-Flag. Furthermore, the synthetic oli-
gonucleotide encoding the NLS (213ERRRRF218) re-
gion of MITF was subcloned into pEGFP-N1 (Sigma, St
Louis, WA, USA) at EcoR I/BamH I site to add a NLS to
the N-terminus of GFP. All constructs were verified by
direct nucleotide sequencing.
Cell culture, Transfections, and Luciferase Reporter
Assays
The melanoma UACC903 cells or NIH3T3 cells were
grown at 37°C under 5% CO2 in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and 100U/ml of penicillin/strepto-
mycin. 24 h before transfection, cells were seeded at an
approximate 50% confluency in 24-well plates. Cells
were transfected with 5 ng of the reporter plasmid and
20 ng of the expression plasmid, using Lipofectamine
2000 reagent (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s protocol, and 5 ng of pC-
MV-β-gal (BD biosciences/Clontech, Palo Alto, CA,
USA) was included for normalization of transfection effi-
ciency. The final DNA amount of each well was adjusted
to 200 ng with empty vectors. At 48 h after transfection,
cells were washed with phosphate buffered saline (PBS)
and lysed with Reporter Lysis Buffer (Promega, Madi-
son, WI, USA). The extracts were assayed for luciferase
and β-galactosidase activity. Luciferase reporter assays
were performed using Luciferase Assay System (Pro-
mega, Madison, WI, USA) according to the manufactur-
er’s protocol. Luciferase activities were determined us-
ing SIRIUS luminometer (Berthold Detection Systems
GmbH, Pforzheim, Germany). As for competition as-
says, various amounts of mutant MITF plasmids (20 ng,
40 ng, 80 ng) were mixed with a fixed amount of WT
MITF (20 ng) and the reporter TYR plasmid (5 ng) in
the transfection. All reporter assays were conducted at
least three times and performed in triplicate on different
days using different batches of cells. Data were analyzed
using Prism 4 software (GraphPad, Software Inc., San
Diego, CA, USA).
Western Blot Assays
The melanoma UACC903 cells were transfected with
200 ng of Flag-MITF or its mutant constructs using Lipo-
fectamine 2000 reagent (Invitrogen, Carlsbad, CA,
USA) in 12-well plates. At 48 h after transfection, cells
were lysed in 2 × SDS loading buffer, containing 1 mM
phenylmethanesulfonyl fluoride (PMSF) (Sigma, St Lou-
is, WA, USA), and 0.2 mM β-mercaptoethanol supple-
mented with protease inhibitor cocktail (Sigma, St Lou-
is, WA, USA). Proteins were separated on sodium dodec-
yl sulfate polyacrylamide gels (SDS-PAGE) and trans-
ferred onto a polyvinylidene fluoride (PVDF) membrane
(Millipore, Billerica, MA, USA) in the presence of 20%
methanol. The membrane was blocked in Tris-buffered
saline supplemented with 5% non-fat milk for 1 h at
room temperature and then incubated overnight at 4° C
with mouse monoclonal anti-Flag M2 antibody (1:1000
dilution, Sigma, St Louis, WA, USA). After washing
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with Tris-buffered saline supplemented with 0.1% Tween
20 (Sigma, St Louis, WA, USA), the membrane was in-
cubated for 1 h at room temperature with a horseradish per-
oxidase-conjugated secondary anti-mouse IgG antibody
(1:10000 dilution, Sigma, St Louis, WA, USA). Detection
were performed using the ECL plus Western blotting de-
tection system (GE Healthcare, Chalfont St. Giles, Buck-
inghamshire, UK) according to manufacturer’s instruction.
Biotinylated DNA Affinity Precipitation
The MITF-binding oligonucleotide,
5’-GAAAAGTCAGTCATGTGCTTTTCAG-3’, probe
oligo-DNA derived from the promoter of human TYR
gene, was biotinylated at the 5’-terminus, and then an-
nealed with its complementary strand to generate a dou-
ble-stranded oligonucleotide. The melanoma UACC903
cells were transfected with Flag-MITF, Flag-R217I,
Flag-T192fsX18, or Flag-N210K using Lipofectamine
2000 reagent in 6-well plates. 48 h after transfection,
293T cells were lysed by sonication in HKMG buffer
(10 mM HEPES, pH 7.9, 100 mM KCl, 5 mM MgCl2,
10% glycerol, 1 mM DTT, and 0.5% of Nonidet-P40)
containing protease inhibitors. Cellular debris was re-
moved by centrifugation. 10% cell lysates were extract-
ed and added 2×SDS/0.2 mM β-mercaptoethanol for in-
put immunoblotting. Remaining cell lysates were
brought to a final volume of 1 ml and precleared with 30
μl streptavidin-agarose beads (Sigma, St Louis, WA,
USA) with rotation at 4°C for 1 h, then incubated with
or without 8 μg of biotinylated double-stranded oligonu-
cleotide and 10 μg of poly(dI-dC).poly(dI-dC) (Sigma,
St Louis, WA, USA) with rotation at 4°C for 20 h. 40 μl
streptavidin-agarose beads were added and samples were
incubated for another 2 h at 4°C. Beads/DNA/protein or
beads/protein complexes were washed three times using
cold ice HKMG buffer and resuspended in 2 × SDS/0.2
mM β-mercaptoethanol. Samples were boiled at 95° C
for 10 minutes and subsequently separated on 12%
SDS-PAGE. Anti-Flag M2 antibody was used in the sub-
sequent immunoblotting.
Immunofluorescence Assays
The NIH3T3 cells were plated on 24-well plates and
transfected with 50 ng of each MITF constructs. At 48 h
after transfection, cultures were fixed in 4% paraformal-
dehyde for 30 min at room temperature. After permeabi-
lized for 1 h in PBS/0.2% Triton X-100 (Bio Basic Inc,
Bailey Avenue Amherst, NY, USA), they were incubated
with blocking solution (PBS, 3% bovine serum albumin,
5% goat serum) for 1 h. Incubation with primary an-
ti-Flag M2 (1:600 dilution) was performed at 4°C over-
night. After washed with PBS/0.2% Triton X-100 three
times, fluorescence-labeled secondary anti-mouse anti-
bodies (1:300 dilution; Invitrogen, Carlsbad, CA, USA)
were incubated for 2 h in a dark room. After incubation
of 4,6-diamino-2-phenylindole (DAPI; Invitrogen, Carls-
bad, CA, USA) for 3 minutes, cells were mounted in Flu-
oromount medium (Sigma, St Louis, WA, USA) and flu-
orescence images were examined with a laser scanning
confocal system installed on a Carl Zeiss microscope
(Zeiss, Göttingen, Germany) with a 63 × oil immersion
objective. Images were analyzed using the Metaphor
software package.
Results
Mutations of MITF in WS2 and TS Patients
We previously identified two heterozygous mutations
c.650G>T (p.R217I) and c.575delC (p.T192fsX18) in
the MITF genes in three WS2 cases, presenting with
deafness and heterochromia irides. The p.R217I is a mis-
sense mutation found in the basic domain of bHLHZip
region of exon 7, causing an arginine to isoleucine substi-
tution at codon 217 (Fig. 1A). The p.T192fsX18 is a
frameshift mutation which generates different sequences
starting at position 192 in exon 6 and introduces a prema-
ture stop codon at position 210 (Fig. 1A), resulting in
truncated protein without bHLHZip domain and transac-
tivation domain. The TS-causative missense mutation,
c.630C>G (p.N210K), is located in the basic domain of
bHLHZip region, resulting in substitution of lysine for
asparagines in the mutant protein (Fig. 1A).
Transcription Activity of Mutant MITFs
MITF can induce the expression of target gene TYR
and subsequently the expression of the melanocyte-spe-
cific enzyme tyrosinase [8，22]. A luciferase reporter con-
struct containing approximately 300 bp of the TYR pro-
moter sequences was used to study if diseases-associated
mutations affected MITF activity. As shown in Fig. 1B,
WT MITF was able to increase the TYR promoter activi-
ty by about 18-fold, consistent with previous reports [21-24].
However, the transactivity of R217I MITF was dramati-
cally reduced as compared with WT, whereas the
T192fsX18 mutant failed to transactivate the TYR pro-
moter, indicating that R217I mutant was partially func-
tional while T192fsX18 mutant was loss-of-function.
Surprisingly, the transcriptional activity of TS-associated
N210K MITF was comparable to WT (Fig. 1B).
Some loss-of-function mutant proteins may compete
with their WT protein binding to the promoter of target
genes and inhibit the activity of WT proteins, ie. domi-
nant negative effect. To determine whether the R217I
and T192fsX18 MITF were able to interfere with WT
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MITF function, we carried out competition assays by co-
transfecting WT MITF and R217I or T192fsX18 expres-
sion plasmids together with the reporter plasmid. Neither
R217I nor T192fsX18 showed inhibitory effect on the
transcriptional activity of WT MITF (Fig. 1C, D).
Figure 1. Functional analysis of WS/TS-associated MITF. A:
Schematic representation of the WT, R217I, N210K, and
T192fsX18 MITF. The bHLH-Zip domain and C-terminal tran-
scriptional activation (TA) domain are shown. R217I and N210K
are missense mutants and the arrow indicates mutation site in ba-
sic domain. T192fsX18 is a frameshfit mutant and the filled box
represents resulting frameshift from mutation site to premature
stop codon. B: Transcriptional activities of MITF and its mutants
determined by luciferase activity assays. The luciferase reporter
plasmid Tyr-Luc were transiently transfected into 293T cells in
combination with WT or mutant MITF expression plasmids. C, D:
Effect of R217I or T192fsX18 mutants on WT MITF transactivity.
Increasing amounts of mutant R217I or T192fsX18 expression
plasmids were cotransfected with a fixed amount of WT MITF ex-
pression plasmid and the luciferase reporter plasmid Tyr-Luc. The
basal level of luciferase was set as 1. Data from all other transfec-
tions are presented as fold induction above this level. Luciferase
activity was normalized by measuring β-galactosidase activity.
Each value shown was the mean ± s.e.m. of three replicates from a
single assay. The results shown were representative of at least
three independent experiments.
Exogenous Expression of MITF Proteins
To investigate whether the disrupted function is caused
by the expression level of mutant MITF, we performed
Western blot analysis on protein extracts from melanoma
UACC903 cells transfected with WT, R217I, or
T192fsX18 MITF plasmid. As shown in Fig. 2, both WT
and mutant MITF proteins were detected at the expected
size. There was no apparent difference between WT and
mutant MITF in the expression level.
Figure 2. Western blot analysis of WT and mutant MITF proteins.
Melanoma UACC903 cells were transiently transfected with plas-
mids expressing either the WT or mutant variants of MITF. Pro-
teins from whole cell lysates were analyzed by SDS-PAGE (12%)
and the expression of MITF was visualized using monoclonal anti-
body against Flag epitope.
DNA Binding Capacity of MITF Mutants
To determine the DNA-binding capacity of WT and
mutant MITFs, we used a biotinylated double-stranded
oligonucleotide containing MITF binding sequence to
precipitate proteins from melanoma UACC903 cells
transfected with WT, T192fsX18, R217I, or N210K
MITF plasmid. As shown in Fig.3A and B, WT, R217I,
and N210K MITFs were able to bind specifically to the
double-stranded DNA, whereas T192fsX18 MITF lost
the DNA-binding ability, consistent with its lack of the
bHLHZip DNA-binding domain.
Figure 3. DNA binding capacity of WS/TS-associated MITF. The
lysates of melanoma UACC903 cells transfected with WT, R217I,
T192fsX18, and N210K MITF plasmids were incubated with or
without biotinylated double-stranded oligonucleotides of the
MITF binding region at the TYR promoter. And the DNA/protein
complex was pulled down with streptavidin-agarose beads. The
precipitated proteins were separated on SDS-PAGE and analyzed
by immunoblotting using anti-Flag M2 antibody. DNA precipita-
tion demonstrates that R217I and N210K mutant retain the
DNA-binding activity (A,B), whereas T192fsX18 mutant lose ca-
pability to bind to DNA (A).
Subcellular Distribution of WT and Mutant MITF
Proteins
As a transcription factor, MITF is localized in the nu-
cleus. Then, we attempted to investigate if mutations al-
tered the subcellular distribution of MITF protein. Immu-
nofluorescence was used to detect the exogenously ex-
pressed proteins. As shown in Fig. 4, WT and R217I
MITF were only localized in the nucleus, whereas
T192fsX18 MITF showed localization in both cytoplasm
and nucleus. These results indicated that WT and R217I
MITF produced in NIH3T3 cells were normally trans-
ported into nuclei while T192fsX18 MITF was defective
in the nuclear translocation.
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Figure 4. Subcelluar localization of WS-associated MITF pro-
teins. WT MITF and its mutant proteins (a, d, g) were shown in
green, DAPI (b, e, h) revealing nucleus was shown in blue, and
the merged images (c, f, i) were shown. Scale bar: 5μm.
Functional Analysis of NLS of MITF
Protein localized in nucleus contains specific NLS and
can be recognized by transport protein to cross nuclear
pore complex (NPC) into nucleus to exert its function.
We speculate that the abnormal cytoplasmic distribution
of T192fsX18 MITF may be due to its loss of NLS. In-
deed, MITF contains a putative NLS (NLIERRRRFNIN)
between aa210-221 of the C-terminal basic domain [23]
(http://cubic.bioc.columbia.edu/predictNLS/). To exam-
ine whether the NLS is necessary for the MITF function,
we made a MITF construct with deletion of aa213-218
(ie. MITF ∆ NLS). As shown in Fig.5A, MITF ∆ NLS
failed to transactivate the TYR promoter. Importantly, the
MITF∆NLS protein was localized exclusively in the cy-
toplasm (Fig.5B).
To examine whether the NLS sequences of MITF is
sufficient to render cytoplamic protein into nuclei, we
tagged the NLS sequence of MITF (ERRRRF) at the
N-terminus of green fluorescence protein (GFP). After
transfected into the NIH3T3 cells, about 15% WT GFP
was distributed in the nucleus, 30% was localized in the
cytoplasm, whereas about 55% was seen in both cyto-
plasm and nucleus (Fig.5C). However, NLS-tagged GFP
significantly increase the nuclei localization to about
80%, and about 20% of NLS-tagged GFP was observed
in both cytoplasm and nuclei, while none of them was
seen in the cytoplasm only (Fig.5C).
Figure 5. Functional analysis of NLS of MITF. A: Transcriptional
activities of WT MITF and MITF∆NLS determined by luciferase
activity assays. The luciferase reporter plasmid Tyr-Luc were tran-
siently transfected into melanoma UACC903 cells in combination
with WT MITF or MITF∆NLS expression plasmid. B: Subcelluar
localization of MITF ∆ NLS in transfected cells was shown in
green, DAPI revealing nucleus was shown in blue, and the merged
images were shown. Scale bar: 5μm. C Frenqency distribution of
GFP and GFP-NLS in transfected cells.
Discussion
MITF encodes a 419-amino-acid transcription factor
containing bHLHZip structure which is considered to
bind DNA by the basic domain, to dimerize via the HLH
domain, and to be stabilized by the Zip domain [1，2]. The
carboxyl terminus of MITF contains a transcriptional ac-
tivation domain and plays an important role in defining
the target genes [9]. The TYR gene, a melanocyte-specific
gene, encodes tyrosinase, is a key enzyme for melanis
synthesis. MITF binds to the specific E-box motif (CAT-
GTG) within the promoter of TYR and initiates its tran-
scription [8，9，22]. Few functional studies have been per-
formed on human diseases-associated MITF mutations.
Two nonsense mutations of MITF causing WS2 were
shown to abrogate DNA binding and transactivation of
the TYR promoter [24]. Another WS2-associated mutation,
c.892T>C (p.S298P), impaired MITF function due to
loss of the phosphorylation site by GSK3β [25]. We have
shown here that WS2-associated T192fsX18 and R217I
mutations attenuated the transactivity of MITF on TYR
promoter. R217I MITF retained the DNA-binding activi-
ty as well as nuclear localization. However, T192fsX18
mutation, lacking of NLS, resulted in abnormal cytoplas-
mic distribution. Moreover, T192fsX18 MITF, without
bHLHZip and transactivation domains, was not able to
bind to the TYR promoter. Nevertheless, none of WS2-as-
sociated MITF mutants showed dominant negative ef-
fect. Haploinsufficiency may be the underlying mecha-
nism for WS2 pathogensis.The surprising finding of our
study is that a TS-associated N210K MITF showed com-
parable in vitro activity as WT MITF. TS patients show a
more severe phenotype of complete penetrance including
profound deafness and generalized hypopigmentation,
whereas WS patients only show mild phenotype such as
patchy depigmentation and incomplete penetrance [17].
It thus has been hypothesized that the N210K mutation
may exert a dominant negative effect. However, N210K
MITF behaved similarly as WT in both in vitro transcrip-
tional activity and DNA-binding assays. Therefore, the
possible involvement of MITF in the pathogenesis of TS
still needs further investigation, especially in animal
models and neural crest cells such as melanocytes.
Protein localized in the nucleus frequently contains
specific NLS that can be recognized by NLS-binding
protein [26，27], and be transported through the nuclear pore
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into the nucleus. The basic domain of MITF may contain
a putative NLS (210NLIERRRRFNIN221) [23] (http://cu-
bic.bioc.columbia.edu/predictNLS/). The T192fsX18 mu-
tant protein lacks NLS, however, it may diffuse to the nu-
cleus due to its small molecular mass (predicted to be 23
kDa) as proteins below 40 kDa are known to cross the
NPC via passive diffusion [28，29]. The R217I mutation in
the NLS did not impair the nuclear localization potential
of MITF, consistent with the mice study carried out by
Takebayashi et al [23]. They found that Mior-MITF encod-
ed by the mouse Mior allele, with a R216K substitution in
the basic domain, showed normal subcellular localiza-
tion. The function of MITF NLS was further demonstrat-
ed by loss-of-function and gain-of-function studies. In
the loss-of-function study, MITF with deletion of NLS
localized exclusively in the cytoplasma and failed to acti-
vate the TYR promoter. Conversely, addition of this NLS
to the N-terminus of GFP enhanced the translocation of
GFP into nucleus.
In summary, we have shown that two recent identified
WS2-associated mutations attenuated the transcriptional
activity of MITF. As both mutations were in the heterozy-
gous form and lack of dominant-negative effect, haploin-
sufficiency is the most reasonable mechanism, where the
normal MITF protein resulted from one copy of the wild
allele does not reach the threshold level necessary for
full function of the protein. However, the TS-associated
mutation, N210K, showed comparable activity as WT
MITF, implying an alternative mechanism for the TS
pathogenesis.
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